Avalon Pharmaceuticals Nominates Lead Clinical Development Candidate in its Beta-catenin Pathway Inhibitor Program
GERMANTOWN, Md.--(BUSINESS WIRE)--Avalon Pharmaceuticals, Inc. (Nasdaq:AVRX), announced today the nomination of AVN316 as a lead clinical development candidate in its Beta-catenin Pathway Inhibitor program. This novel compound inhibits the Beta-catenin pathway and is a potent inducer of cancer cell death. The Company plans to begin clinical testing of AVN316 in patients in 2009.